Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2005 | 09-2005 | 06-2005 | 03-2005 | 12-2004 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -13,275 | -9,762 | -6,061 | -3,193 | -9,091 |
| Depreciation Amortization | 206 | 155 | 111 | 50 | 123 |
| Accounts receivable | -377 | -19 | -46 | N/A | N/A |
| Other Working Capital | -112 | 68 | -210 | 79 | 1,152 |
| Other Operating Activity | 563 | 165 | 193 | 7 | 98 |
| Operating Cash Flow | $-12,996 | $-9,393 | $-6,014 | $-3,057 | $-7,718 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -351 | -344 | -247 | -131 | -228 |
| Investing Cash Flow | $-351 | $-344 | $-247 | $-131 | $-228 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 16,472 | 365 | 313 | 311 | 15,580 |
| Other Financing Activity | 0 | 0 | 0 | 0 | 7,870 |
| Financing Cash Flow | $16,472 | $365 | $313 | $311 | $23,450 |
| Beginning Cash Position | 16,008 | 16,008 | 16,008 | 16,008 | 504 |
| End Cash Position | 19,132 | 6,636 | 10,060 | 13,130 | 16,008 |
| Net Cash Flow | $3,125 | $-9,372 | $-5,947 | $-2,877 | $15,504 |
| Free Cash Flow | |||||
| Operating Cash Flow | -12,996 | -9,393 | -6,014 | -3,057 | -7,718 |
| Capital Expenditure | -351 | -344 | -247 | -131 | -228 |
| Free Cash Flow | -13,347 | -9,737 | -6,261 | -3,188 | -7,946 |